| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Efficacy and safety of 12-week-regimen of sofosbuvir and ledipasvir, and 8- or 12-week regimen of glecaprevir and pibrentasvir were efficacious and safe in patients with recurrent hepatitis C after liver transplantation in our institution and in Japanese multicenter analysis. Diversity of HCV RNA in post-liver transplant and non-liver transplant patients were analyzed by using third-generation sequencing technique. We revealed that multi-drug resistant HCV clones at treatment failure originated from a subpopulation of pre-existing HCV with resistance-associated substitution, and those HCV were selected for and became dominant with the acquisition of multiple resistance-associated substitutions.
|
